- Chemours reported Q4 2024 net sales of $1.36 billion, down 1% year-over-year, driven by a 3% decrease in pricing partially offset by a 2% increase in volume.
- Q4 adjusted EBITDA was $179 million, up 2% year-over-year, driven by cost savings from the TT Transformation Plan, favorable inventory adjustments and higher volumes in TSS, partially offset by lower pricing.
- For full year 2024, net sales were $5.78 billion, down 5% year-over-year due to lower pricing and portfolio changes, while adjusted EBITDA was $786 million, down 22% due to lower pricing, unfavorable currency impacts and higher costs.
- The company provided 2025 adjusted EBITDA guidance of $825-$975 million, expecting growth in Opteon Refrigerants and cost savings from the Pathway to Thrive strategy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.